The positive performance of Ascendis Pharma over the past 5 years, with an average annual return of 15.86%, indicates a strong growth trajectory. This performance, coupled with a substantial market capitalization of $8.02 billion, suggests a positive outlook for the stock in the short term. The historical data provided demonstrates the company's ability to outperform the market, which could continue to attract investor interest and potentially drive up the stock price.